KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CRISPR Therapeutics AG (CRSP) Return on Capital Employed: 2016-2025

Historic Return on Capital Employed for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to -0.28%.

  • CRISPR Therapeutics AG's Return on Capital Employed fell 13.00% to -0.28% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.28%, marking a year-over-year decrease of 13.00%. This contributed to the annual value of -0.22% for FY2024, which is 11.00% down from last year.
  • CRISPR Therapeutics AG's Return on Capital Employed amounted to -0.28% in Q3 2025, which was down 2.68% from -0.28% recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Return on Capital Employed peaked at 0.19% during Q2 2021, and registered a low of -0.31% during Q4 2022.
  • Over the past 3 years, CRISPR Therapeutics AG's median Return on Capital Employed value was -0.22% (recorded in 2024), while the average stood at -0.21%.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Return on Capital Employed surged by 37bps in 2021, and later crashed by 45bps in 2022.
  • Quarterly analysis of 5 years shows CRISPR Therapeutics AG's Return on Capital Employed stood at 0.14% in 2021, then plummeted by 45bps to -0.31% in 2022, then rose by 20bps to -0.11% in 2023, then decreased by 11bps to -0.22% in 2024, then declined by 13bps to -0.28% in 2025.
  • Its Return on Capital Employed stands at -0.28% for Q3 2025, versus -0.28% for Q2 2025 and -0.23% for Q1 2025.